JPRN-UMIN000034592已完成未知
Comparative clinical study of alilocumab (Praluent) and evorocumab (Repatha) for dyslipidemia - Alilocumab and evorocumab for dyslipidemia
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who were deemed not appropriate to participate in this study by doctor
研究者
相似试验
已完成
3 期
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)HypercholesterolaemiaNCT02585778Sanofi517
已完成
4 期
Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With HypercholesterolemiaAcute Coronary SyndromeHypercholesterolemiaNCT02984982Sanofi206
已完成
4 期
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)DyslipidemiaNCT02642159Sanofi413
尚未招募
Unknown
A comparative study of EVOlocumab and high-intensity statin for EARLY and intensive LDL-Cholesterol reduction in patients with acute coronary syndrome; Multi-center, prospective, randomized, double blinded, sham-procedure and placebo controlled trialKCT0009668BUCHEON SEJONG HOSPITA108
已完成
不适用
Effect of Alirocumab(proprotein convertase subtilisin/kexin type9 inhibitor) and Rosuvastatin or Rosuvastatin alone on lipid core plaques in coronary artery disease evaluated by near-infrared spectroscopy intravascular ultrasoundangina pectorisJPRN-UMIN000031243Kobe University,department of cardiology30